ArriVent Biopharma releases corporate presentation on late-stage oncology pipeline led by firmonertinib in EGFR-mutant NSCLC
AVBP•Pipeline and cash position update
ArriVent said its ADC pipeline included ARR-217 in Phase 1 for GI tumors, with ARR-002 cleared for a U.S. Phase 1 start in solid tumors.
Cash and cash equivalents totaled USD 373.1 million as of June 30, 2026.
Corporate presentation highlights lead oncology programs
ArriVent highlighted firmonertinib as its lead program, targeting first-line EGFR exon 20 insertion mutant NSCLC under FDA Breakthrough Therapy Designation.
- Enrollment completed in the global Phase 3 FURVENT study in first-line EGFR exon 20 insertion NSCLC, with 398 patients enrolled.
- The global Phase 3 ALPACCA trial in first-line EGFR PACC mutant NSCLC targets 480 patients, comparing firmonertinib 240 mg vs. osimertinib or afatinib.
